This handout photo obtained May 26, 2021, courtesy of Pharmaceutical company Merck shows capsules of the experimental antiviral drug Molnupiravir. Merck has submitted the application for molnupiravir, which it said earlier this month was shown to reduce hospitalizations by 50 percent. It said it was working "with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months." "That is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data," he added. Of the patients who received molnupiravir, 7.3 percent were hospitalized by day 29, compared to 14.1 percent of those on a placebo — a relative risk reduction of around 50 percent.

Source: Manila Times October 11, 2021 11:15 UTC